• Explore /
  • Poster
  • / Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.

Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.

Abstract Poster

Authors

Georg Pfeiler

Georg Pfeiler

Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria

Georg Pfeiler , Robert Konigsberg , Christian Fesl , Brigitte Mlineritsch , Herbert Stoger , Christian F. Singer , Sabine Poestlberger , Guenther G. Steger , Michael Seifert , Peter Christian Dubsky , Raimund Jakesz , Hellmut Samonigg , Vesna Bjelic-Radisic , Richard Greil , Christian Marth , Michael Gnant

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT00295646

Citation

J Clin Oncol 30, 2012 (suppl; abstr 514)

DOI

10.1200/jco.2012.30.15_suppl.514

Abstract #

514

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: G. Pfeiler

First Author: Georg Pfeiler

First Author: M. Gnant

First Author: Megan Elizabeth Tesch